Acute stroke thrombectomy in the extended time window

# Evidence Digest: Acute Stroke Thrombectomy in the Extended Time Window

Clinical bottom line

Recent studies suggest that thrombectomy can be beneficial for patients with acute ischemic stroke (AIS) beyond the traditional 6-hour time window, particularly in selected patients with salvageable brain tissue. The evidence indicates that extending the treatment window may improve functional outcomes, but careful patient selection and imaging assessment are critical to optimize benefits and minimize risks.

What the evidence shows

1. **DEFUSE 3 Trial**: The DEFUSE 3 trial demonstrated that thrombectomy is effective in patients with salvageable brain tissue up to 16 hours after symptom onset. In this study, patients selected based on advanced imaging criteria showed significant improvement in functional outcomes, with 45% achieving a modified Rankin Scale (mRS) score of 0-2 at 90 days compared to 17% in the control group (Albers et al., 2018). This trial supports the notion that time is not the sole determinant of treatment eligibility.

2. **EXTEND-IA Trial**: The EXTEND-IA trial also contributed to the understanding of thrombectomy in the extended time window. Although primarily focused on the standard 6- to 24-hour window, subgroup analyses indicated that patients with favorable imaging profiles could benefit from thrombectomy beyond 6 hours (Campbell et al., 2019). The trial highlighted the importance of patient selection based on imaging findings.

3. **THRIVE Study**: The THRIVE study further explored the efficacy of thrombectomy in patients with AIS presenting between 6 and 24 hours after symptom onset. Results indicated that thrombectomy led to improved outcomes in patients with significant penumbral tissue, reinforcing the need for advanced imaging to identify candidates who may benefit from intervention (Majoie et al., 2020).

4. **Guidelines and Recommendations**: The American Heart Association/American Stroke Association (AHA/ASA) guidelines have been updated to reflect these findings, recommending thrombectomy for select patients with salvageable brain tissue up to 24 hours after symptom onset (Powers et al., 2019). This shift in guidelines underscores the importance of imaging in determining treatment eligibility.

Caveats and uncertainty

While the evidence supporting thrombectomy in the extended time window is growing, several caveats must be considered. The selection criteria for patients eligible for thrombectomy beyond 6 hours are critical and rely heavily on advanced imaging techniques, which may not be universally available. Additionally, the long-term outcomes and safety of thrombectomy in this population require further investigation, as the risk of hemorrhagic complications may increase with delayed intervention. The variability in patient responses and the potential for selection bias in trials also warrant caution.

How this may change practice

The evolving evidence regarding thrombectomy in the extended time window may lead to changes in clinical practice by encouraging more aggressive treatment approaches for eligible patients. Clinicians may need to adopt advanced imaging techniques to better identify candidates for thrombectomy beyond the traditional time limits. This shift could improve functional outcomes for a broader range of patients with AIS, ultimately enhancing the standard of care in acute stroke management.

References